Updates are available Correction dated 2023-01-25
Click to view Correction: https://doi.org/10.1007/s12185-023-03543-9
-
Authors
Kanda, Yoshinobu https://orcid.org/0000-0002-4866-9307
Mori, Takehiko
Narita, Atsushi
Wolter, Kevin D.
Yoshimatsu, Hiroki
Nishimura, Kazuma
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04350606 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series
https://doi.org/10.1007/s12185-022-03496-5
-
Funding
Funding for this research was provided by:
Pfizer Inc
- License Information
-
More Information
Article History
Received: 27 June 2022
Revised: 10 November 2022
Accepted: 10 November 2022
First Online: 28 November 2022
Change Date: 25 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12185-023-03543-9
Declarations
:
: YK, TM, and AN have no conflicts to declare. KDW is an employee and shareholder of Pfizer Inc. KN is an employee and shareholder of Pfizer R&D Japan. HY is an employee of Pfizer R&D Japan.
